大脑静脉鼻血栓症的双重血栓性突变:一个案例报告强调血栓性查和不确定的抗凝血
Yu Sun1, Weijing Liang1, Liqiao Zhao1
1Department of Neurology, Taiyuan Central Hospital, Taiyuan, CHN.
Cureus
|September 30, 2025
概括
大脑静脉鼻血栓塞 (CVST) 的风险增加与MTHFR和PAI-1基因变异. 终身抗凝药对于预防遗传性血栓友病患者复发至关重要.
科学领域:
- 神经学 神经学
- 遗传学 遗传学 是一个
- 血液学 血液学 血液学
背景情况:
- 大脑静脉鼻血栓症 (CVST) 是一种罕见的中风亚型,通常与遗传性血栓症有关.
- 遗传倾向可以增加血栓事件的风险.
研究的目的:
- 报告一种与同时存在的MTHFR C677T突变和PAI-1 4G/5G多态性相关的CVST病例.
- 强调在CVST患者中进行综合性血栓性查的重要性.
主要方法:
- 一个40岁的男性患有CVST的病例报告.
- 诊断工作包括磁共振静脉扫描和血栓友爱查.
- 治疗包括抗凝剂和维生素B补充剂.
主要成果:
- 证实了CVST,查显示了异合体的MTHFR C677T和PAI-1 4G/5G变体.
- 抗凝治疗导致症状消失和持续缓解.
- 停止治疗导致血栓复发,突出显示无限期治疗的必要性.
结论:
- 同时存在的MTHFR C677T和PAI-1 4G/5G变体在CVST中构成协同性血栓风险.
- 综合性血栓性查对于指导长期抗凝策略至关重要.
- 终身抗凝固固守法对于预防遗传性高凝固状态的复发至关重要.
相关概念视频
Venous Thrombosis III: Interprofessional Care
280
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
280
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
294
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
294
Venous Thrombosis I: Introduction
373
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
373
Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.7K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.7K
Venous Thrombosis IV: Nursing Management
201
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
201
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.1K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.1K


